Compare Arko Corp. (ARKO) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs DexCom, Inc. — how do they compare? Arko Corp. trades at $4.63 (market cap $493.06M), while DexCom, Inc. trades at $89.04 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 68.5× Arko Corp.'s market cap, and Arko Corp. pays a 2.73% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| ARKO | DXCM | |
|---|---|---|
Market Cap | $493.06M | $33.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $89.53 |
52-Week Low | $3.82 | $54.84 |
Enterprise Value | $2.67B | $33.24B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.45, down 5.32% amid weak Q2 2026 earnings that missed estimates. The stock is in a bearish technical trend with key support at $4. Revenue has declined from $9.4B in 2023 to $7.6B in 2025, though net income margins remain thin at 0.19%. Recent news highlights pressure from softer retail demand and elevated fuel costs, despite management maintaining full-year EBITDA guidance.
The outlook is cautious with 100% hold ratings from analysts, reflecting concerns over margin compression and volatile consumer spending. Risks include high debt levels and competitive pressures, but the company's consistent dividend payments and positive operating cash flow offer some stability. Further price movement hinges on execution against guidance and macroeconomic conditions.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
